Capricor Therapeutics Shares Climb as Analysts Project Profitability by 2028

Dow Jones

Dec 09

By Katherine Hamilton

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028.

The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the session. Shares have more than doubled this year.

Oppenheimer analysts Lelan Gershell and Rohan Mathur on Monday raised their price target to $54 from $22. The boost is related to positive results from Capricor's drug candidate deramiocel, which the San Diego biotechnology company reported earlier this month.

Gershell and Mathur believe the Food and Drug Administration will approve deramiocel by mid-2026, based on the results, they said in a note. Deramiocel met the primary endpoint and key secondary cardiac endpoint in a phase 3 trial for treating Duchenne muscular dystrophy.

The analysts also believe Capricor's financing will allow it to achieve profitability by 2028, thanks to the underwritten public offering of 6 million shares that Capricor announced on Friday. Shares will be priced at $25 apiece, Capricor said.

Gershell and Mathur expect Capricor to hit $1.1 billion in U.S. sales by 2031.

"We believe deramiocel's clinical profile stands second to none relative to approved DMD therapeutics," they said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 08, 2025 12:21 ET (17:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590357475"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590357475\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590357475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 01:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590357475","market":"sh","top_or_hot":-1,"title":"Capricor Therapeutics Shares Climb as Analysts Project Profitability by 2028","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares gained after analysts said they believe the company can achieve profitability by 2028. \n</p>\n<p>\n  The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the session. Shares have more than doubled this year. \n</p>\n<p>\n  Oppenheimer analysts Lelan Gershell and Rohan Mathur on Monday raised their price target to $54 from $22. The boost is related to positive results from Capricor's drug candidate deramiocel, which the San Diego biotechnology company reported earlier this month. \n</p>\n<p>\n  Gershell and Mathur believe the Food and Drug Administration will approve deramiocel by mid-2026, based on the results, they said in a note. Deramiocel met the primary endpoint and key secondary cardiac endpoint in a phase 3 trial for treating Duchenne muscular dystrophy. \n</p>\n<p>\n  The analysts also believe Capricor's financing will allow it to achieve profitability by 2028, thanks to the underwritten public offering of 6 million shares that Capricor announced on Friday. Shares will be priced at $25 apiece, Capricor said. \n</p>\n<p>\n  Gershell and Mathur expect Capricor to hit $1.1 billion in U.S. sales by 2031. \n</p>\n<p>\n  \"We believe deramiocel's clinical profile stands second to none relative to approved DMD therapeutics,\" they said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 08, 2025 12:21 ET (17:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Capricor Therapeutics Shares Climb as Analysts Project Profitability by 2028</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCapricor Therapeutics Shares Climb as Analysts Project Profitability by 2028\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-09 01:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Capricor <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares gained after analysts said they believe the company can achieve profitability by 2028. \n</p>\n<p>\n  The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the session. Shares have more than doubled this year. \n</p>\n<p>\n  Oppenheimer analysts Lelan Gershell and Rohan Mathur on Monday raised their price target to $54 from $22. The boost is related to positive results from Capricor's drug candidate deramiocel, which the San Diego biotechnology company reported earlier this month. \n</p>\n<p>\n  Gershell and Mathur believe the Food and Drug Administration will approve deramiocel by mid-2026, based on the results, they said in a note. Deramiocel met the primary endpoint and key secondary cardiac endpoint in a phase 3 trial for treating Duchenne muscular dystrophy. \n</p>\n<p>\n  The analysts also believe Capricor's financing will allow it to achieve profitability by 2028, thanks to the underwritten public offering of 6 million shares that Capricor announced on Friday. Shares will be priced at $25 apiece, Capricor said. \n</p>\n<p>\n  Gershell and Mathur expect Capricor to hit $1.1 billion in U.S. sales by 2031. \n</p>\n<p>\n  \"We believe deramiocel's clinical profile stands second to none relative to approved DMD therapeutics,\" they said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 08, 2025 12:21 ET (17:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590357475","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590357475","pubTimestamp":1765214460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028.The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the session. Shares have more than doubled this year.Oppenheimer analysts Lelan Gershell and Rohan Mathur on Monday raised their price target to $54 from $22. The boost is related to positive results from Capricor's drug candidate deramiocel, which the San Diego biotechnology company reported earlier this month.Gershell and Mathur believe the Food and Drug Administration will approve deramiocel by mid-2026, based on the results, they said in a note. Deramiocel met the primary endpoint and key secondary cardiac endpoint in a phase 3 trial for treating Duchenne muscular dystrophy.The analysts also believe Capricor's financing will allow it to achieve profitability by 2028, thanks to the underwritten public offering of 6 million shares that Capricor announced on Friday. Shares will be priced at $25 ap","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CAPR":"Capricor Therapeutics Inc"},"translate_title":"分析师预计到2028年将实现盈利，Capricor Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAPR":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. \n\n\n  The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the session. Shares have more than doubled this year. \n\n\n  Oppenheimer analysts Lelan Gershell and Rohan Mathur on Monday raised their price target to $54 from $22. The boost is related to positive results from Capricor's drug candidate deramiocel, which the San Diego biotechnology company reported earlier this month. \n\n\n  Gershell and Mathur believe the Food and Drug Administration will approve deramiocel by mid-2026, based on the results, they said in a note. Deramiocel met the primary endpoint and key secondary cardiac endpoint in a phase 3 trial for treating Duchenne muscular dystrophy. \n\n\n  The analysts also believe Capricor's financing will allow it to achieve profitability by 2028, thanks to the underwritten public offering of 6 million shares that Capricor announced on Friday. Shares will be priced at $25 apiece, Capricor said. \n\n\n  Gershell and Mathur expect Capricor to hit $1.1 billion in U.S. sales by 2031. \n\n\n  \"We believe deramiocel's clinical profile stands second to none relative to approved DMD therapeutics,\" they said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 12:21 ET (17:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}